A Randomized, Open-Label, Parallel-Controlled Phase IIb Clinical Trial of PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection Integrated With 18F-FDG for the Assessment of Myocardial Viability in Patients With Ischemic Cardiomyopathy
Latest Information Update: 05 Mar 2026
At a glance
- Drugs XTR 003 (Primary)
- Indications Cardiomyopathies; Coronary artery disease; Ischaemic heart disorders; Ventricular dysfunction
- Focus Diagnostic use
- Sponsors Sinotau Pharmaceuticals
Most Recent Events
- 05 Mar 2026 New trial record